Evidence of a Significant Role for Fas-Mediated Apoptosis in HCV Clearance during Pegylated Interferon plus Ribavirin Combination Therapy

Abstract

Background

The role of apoptosis in treatment-induced HCV clearance is controversial. We sought to assess the kinetics of serum apoptosis-related cytokines during pegylated interferon-α2a or -α2b plus weight-based ribavirin therapy for genotype 1 chronic HCV infection.

Methods

Serum levels of soluble Fas (sFas), soluble Fas ligand (sFasL) and soluble tumour necrosis factor receptor I (sTNF-RI) were measured at baseline, week 12 and 24 weeks after the end of therapy.

Results

Sustained virological response (SVR) was achieved in 46% of the 164 included patients, 29% had a non-response (NR) and 25% had relapse (RR). NR patients presented with higher levels of sFasL at baseline and lower levels of sTNF-RI at week 12 as compared to RR and SVR patients. Lower concentrations of sFas were observed in SVR patients 24 weeks after treatment as compared to RR and NR patients. An increase in sFas at week 12 followed by a significant drop 24 weeks after therapy was observed among SVR patients. An increase in sFasL during and after treatment was observed in RR and SVR patients. NR patients exhibited an earlier drop in sTNF-RI levels as compared to RR and SVR patients.

Conclusions

Virological response during HCV therapy was associated with an increase of sFas and sFasL, and maintenance of increased concentrations of sTNF-RI.

References

Lavanchy

The global burden of hepatitis C. Liver Int 2009; 29: 74–81.

Hoofnagle

J.H.

Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26 Suppl 3: 15S–20S.

Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20–29.

Kew

Hepatitis C virus and hepatocellular carcinoma in developing and developed countries. Viral Hepat Rev 1998; 4: 259–269.

Gale

Jr. , Foy

E.M.

Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939–945.

Bowen

D.G.

, Walker

C.M.

Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436: 946–952.

Pawlotsky

J.M.

Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 2004; 12: 96–102.

Neumann

A.U.

, Lam

N.P.

, Dahari

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103–107.

Pawlotsky

J.M.

Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006; 43 Suppl 1: S207–S220.

10.

Maag

, Castro

, Hong

, Cameron

C.E.

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001; 276: 46094–46098.

11.

Leyssen

, Balzarini

, De Clercq

, Neyts

The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 2005; 79: 1943–1947.

12.

Feld

J.J.

, Hoofnagle

J.H.

Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967–972.

13.

Castelli

J.C.

, Hassel

B.A.

, Wood

K.A.

A study of the interferon antiviral mechanism: apoptosis activation by the 2–5A system. J Exp Med 1997; 186: 967–972.

14.

Meier

, Bürger

, Mihm

, Saile

, Ramadori

Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection. J Med Virol 2003; 69: 50–58.

15.

Iio

, Hayashi

, Mita

Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 1998; 29: 517–523.

16.

El Bassiouny

A.E.

, El-Bassiouni

N.E.

, Nosseir

M.M.

Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma. Medscape J Med 2008; 10: 130.

17.

Toyoda

, Kakizaki

, Horiguchi

Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C. Liver 2000; 20: 305–311.

18.

Neuman

M.G.

, Benhamou

J.P.

, Marcellin

Cytokine– chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 2007; 149: 126–136.

19.

Zylberberg

, Rimaniol

A.C.

, Pol

Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999; 30: 185–191.

20.

Realdon

, Pontisso

, Adami

High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. J Hepatol 2001; 34: 723–729.

21.

Cascino

, Fiucci

, Papoff

, Ruberti

Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154: 2706–2713.

22.

Papoff

, Cascino

, Eramo

, Starace

, Lynch

D.H.

, Ruberti

An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156: 4622–4630.

23.

Cheng

, Zhou

, Liu

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759–1762.

24.

Gruss

H.J.

Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res 1996; 26: 143–159.

25.

Van Zee

K.J.

, Kohno

, Fischer

, Rock

C.S.

, Moldawer

L.L.

, Lowry

S.F.

Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 1992; 89: 4845–4849.

26.

Itoh

, Okanoue

, Ohnishi

Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1999; 94: 1332–1340.

27.

Kallinowski

, Haseroth

, Marinos

Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998; 111: 269–277.

28.

Scheuer

P.J.

Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372–374.

29.

Fischer

, Baumert

, Blum

H.E.

Hepatitis C virus infection and apoptosis. World J Gastroenterol 2007; 13: 4865–4872.

30.

Okazaki

, Hino

, Fujii

, Kobayashi

, Okita

Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996; 41: 2453–2458.

31.

Kakiuchi

, Yuki

, Iyoda

, Sugiyasu

, Kaneko

, Kato

Circulating soluble Fas levels in patients with hepatitis C virus infection and interferon therapy. J Gastroenterol 2004; 39: 1189–1195.

32.

Ohkawa

, Hiramatsu

, Mochizuki

Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: relationship to the therapeutic response. J Gastroenterol Hepatol 2001; 16: 1009–1014.

33.

Zekri

A.R.

, Haleem

H.A.

, Esmat

G.E.

Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. J Viral Hepat 2007; 14: 468–477.

34.

Hiramatus

, Hayashi

, Kasahara

Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 1995; 22: 135–142.

35.

Bruno

, Manzin

, Roncalli

Histological changes but not virus eradication refect biochemical improvement in chronic hepatitis C patients showing a long-term response to interferon alpha therapy. Ital J Gastroenterol Hepatol 1997; 29: 31–37.

36.

Kakumu

, Okumura

, Ishikawa

Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol 1997; 109: 458–463.

37.

Torre

, Rossol

, Pelli

, Basso

, Delfino

, Picciotto

Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. Clin Exp Immunol 2004; 136: 507–512.